Mechanisms Promoting Angiogenesis in Glioblastoma
促进胶质母细胞瘤血管生成的机制
基本信息
- 批准号:8482555
- 负责人:
- 金额:$ 34.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-03-01 至 2018-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAngiogenic FactorAntibodiesAntibody TherapyApoptosisBindingBiological AssayBlocking AntibodiesBlood VesselsBrainCell ProliferationCellsCessation of lifeCharacteristicsCoculture TechniquesConditioned Culture MediaConfocal MicroscopyDataDevelopmentDown-RegulationEndothelial CellsEphrin-B2ExhibitsGene Expression ProfileGlioblastomaGliomaImmuneImmunocompetentIn SituIndividualInjection of therapeutic agentIntegrinsLaser Scanning MicroscopyLinkMalignant NeoplasmsMediatingMesenchymal Cell NeoplasmMessenger RNAModelingMolecularMusMutationNeural Cell Adhesion Molecule L1PatientsPeptidesPhotonsPlatelet-Derived Growth FactorPlayProcessProliferation MarkerProteinsRecombinant ProteinsRecombinantsRegimenSignal TransductionSliceStem cellsTestingTherapeuticTumor AngiogenesisTumor Stem CellsTumor VolumeUp-RegulationVascular Endothelial Growth Factor ReceptorVascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factorsangiogenesisantiangiogenesis therapybasecell motilityimprovedin vivomigrationmigration stimulating factormutantneoplastic cellneutralizing antibodynovelpublic health relevancereceptorrelating to nervous systemtherapeutic angiogenesistherapeutic targettumor
项目摘要
DESCRIPTION (provided by applicant): Angiogenesis is a prominent characteristic of glioblastoma tumors (GBM) and is considered a promising therapeutic target. Currently available anti-VEGF therapy does not change overall survival, however, and the issue of potential differences in angiogenesis among the molecular subtypes of GBM has not been addressed. Our preliminary data support the concept that glioma stem cells (GSCs) play a key role in GBM-associated angiogenesis and they do so, at least in part, by enhancing the migration of endothelial cells (ECs). ECs isolated from GBM exhibit greatly enhanced migration as compared to ECs isolated from normal brain and this heighted motility is promoted by GSC-conditioned media (GSC-CM). The effects of GSC-CM on the ECs appear to be associated, in part, with upregulation of the pro-angiogenic molecule ephrin-B2 on the ECs based on array analysis and blocking studies using recombinant ephrin-B2-Fc and EphB4-Fc (the ephrin-B2 receptor). This suggests that factors secreted by GSCs, including VEGF, act by upregulating ephrin-B2. In addition, the data indicate that a direct interaction between GSCs and ECs further promotes EC motility and that this interaction is mediated, in part, by an interaction between integrin ¿v¿3 on ECs and L1 cell adhesion molecule (L1CAM) on GSCs. Notably, as ephrin-B2 promotes the activation and signaling of VEGFR2 and as VEGFR2 and integrin ¿v¿3 reciprocally activate each other, these two mechanisms could intersect resulting in ephrin-B2 indirectly activating integrin ¿v¿3. Thus, we propose a hypothetical model in which angiogenesis in GBM is promoted by increased EC motility that is driven by GSC-secreted factors that upregulate pro- angiogenic molecules on EC and that this mechanism enhances the effects of a direct interaction between L1CAM on the GSCs and integrin ¿v¿3 on the ECs. This hypothesis will be tested using GSCs and ECs isolated from GBM of the mesenchymal and pro-neural subtypes using recombinant proteins, antibodies and downregulation approaches to: (1) Determine whether GSC-secreted factors (including VEGF) promote EC migration, proliferation and tubulomorphogenesis and expression of pro-angiogenic molecules (including ephrin-B2 and EphB4) on ECs. (2) Determine whether the interaction of integrin ¿v¿3 on ECs with L1CAM on GSCs transmits a signal promoting EC migration, proliferation and/or tubulomorphogenesis as determined by co-culture of ECs and GSCs; stimulation with GSC-CM; and injection of ECs and GSCs into brain slices followed by 2-Photon Laser Scanning microscopy and individual cell motility tracking. (3) The mechanism will be tested in vivo by determining if the absence/blocking of integrin ¿v¿3 or ephrin-B2 on ECs and L1CAM on GSCs alters angiogenesis, tumor volume and/or survival using PDGF-B-driven GFP-GBM cells or shL1CAM- GFP-GBM cells propagated in immunocompetent integrin ¿3-mutant or control mouse brain. RELEVANCE: These studies have the potential to provide a paradigm shift in the understanding of tumor-associated angiogenesis in general and will suggest novel regimens for improved anti-angiogenesis therapy in GBM.
描述(由适用提供):血管生成是胶质母细胞瘤肿瘤(GBM)的突出特征,被认为是有前途的治疗靶标。但是,目前可用的抗VEGF疗法并未改变总体生存率,并且尚未解决GBM分子亚型中血管生成的潜在差异问题。我们的初步数据支持了胶质瘤干细胞(GSC)在与GBM相关的血管生成中起关键作用的概念,并且至少部分通过增强内皮细胞(ECS)的迁移来做到这一点。与从正常大脑分离的EC相比,从GBM中分离出的EC非常增强,并且通过GSC条件培养基(GSC-CM)促进了这种高度运动。 GSC-CM对EC的影响似乎部分与基于阵列分析和使用重组Ephrin-B2-FC和EphB4-FC(Ephrin-B2受体)的阵列分析和阻断研究的前血管生成分子Ephrin-B2对ECS的上调有关。这表明,包括VEGF在内的GSC分泌的因素通过上调ephrin-b2来起作用。此外,数据表明GSC与EC之间的直接相互作用进一步促进了EC运动,并且这种相互作用部分是由于ECS上的整合素€3与GSC上的L1细胞粘附分子(L1CAM)之间的相互作用介导的。值得注意的是,由于Ephrin-B2促进VEGFR2的激活和信号传导,并且随着VEGFR2和整合素€3互相激活互相激活,这两种机制可以相交,从而相交,从而导致Ephrin b2间接激活整合素€3。这上调了对EC的促血管生成分子,并且这种机制增强了L1CAM在GSCS和ECS中的整合素€3之间直接相互作用的影响。 This hypothesis will be tested using GSCs and ECs isolated from GBM of the mesenchymal and pro-neural subtypes using recombinant proteins, antibodies and downregulation approaches to: (1) Determine whether GSC-secreted factors (including VEGF) promote EC migration, proliferation and tubulomorphogenesis and expression of pro-angiogenic molecules (including ephrin-B2 and ephb4)在EC上。 (2)确定在EC上的整联蛋白上的相互作用是否与GSC上的L1CAM在EC迁移,增殖和/或微型形态发生的信号中是否通过ECS和GSC的共文化确定;用GSC-CM刺激;将EC和GSC注入大脑切片中,然后将2光子激光扫描显微镜和单个细胞运动跟踪。 (3)将通过确定在ECS上整合素€3或Ephrin-B2的不存在/阻塞在体内测试该机制,而GSCS上的L1CAM是否可以通过PDGF-B-B驱动的GFP-GBM细胞或SHL1CAM-GFP-GBM细胞propimant propant propant propant propant propant propant propant propant propant propant propant proptiment of the thy hyl1cAM-gfpp-gbm propoct propoct propoment propoct proppati 脑。相关性:这些研究有可能在对肿瘤相关的血管生成的理解方面提供范式转移,并建议改善GBM抗血管生成治疗的新方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Candece L Gladson其他文献
Candece L Gladson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Candece L Gladson', 18)}}的其他基金
Endogenous synthesis of TRAIL by glioma cancer stem cells and resistance to TRAIL therapy
胶质瘤干细胞内源合成 TRAIL 及对 TRAIL 治疗的耐药性
- 批准号:
10863308 - 财政年份:2023
- 资助金额:
$ 34.28万 - 项目类别:
Endocytic Trafficking of ADCs in GBM cancer stem-like cells
GBM 癌症干细胞样细胞中 ADC 的内吞转运
- 批准号:
10374097 - 财政年份:2019
- 资助金额:
$ 34.28万 - 项目类别:
Endocytic Trafficking of ADCs in GBM cancer stem-like cells
GBM 癌症干细胞样细胞中 ADC 的内吞转运
- 批准号:
9900076 - 财政年份:2019
- 资助金额:
$ 34.28万 - 项目类别:
Endocytic Trafficking of ADCs in GBM cancer stem-like cells
GBM 癌症干细胞样细胞中 ADC 的内吞转运
- 批准号:
10596502 - 财政年份:2019
- 资助金额:
$ 34.28万 - 项目类别:
Endocytic Trafficking of ADCs in GBM cancer stem-like cells
GBM 癌症干细胞样细胞中 ADC 的内吞转运
- 批准号:
9765784 - 财政年份:2019
- 资助金额:
$ 34.28万 - 项目类别:
Mechanisms Promoting Angiogenesis in Glioblastoma
促进胶质母细胞瘤血管生成的机制
- 批准号:
9233971 - 财政年份:2013
- 资助金额:
$ 34.28万 - 项目类别:
Mechanisms Promoting Angiogenesis in Glioblastoma
促进胶质母细胞瘤血管生成的机制
- 批准号:
8816061 - 财政年份:2013
- 资助金额:
$ 34.28万 - 项目类别:
Brain Endothelial TNF-R1 Can Function to Inhibit Angiogenesis
脑内皮 TNF-R1 可以抑制血管生成
- 批准号:
8595299 - 财政年份:2010
- 资助金额:
$ 34.28万 - 项目类别:
Brain Endothelial TNF-R1 Can Function to Inhibit Angiogenesis
脑内皮 TNF-R1 可以抑制血管生成
- 批准号:
8223277 - 财政年份:2010
- 资助金额:
$ 34.28万 - 项目类别:
Brain Endothelial TNF-R1 Can Function to Inhibit Angiogenesis
脑内皮 TNF-R1 可以抑制血管生成
- 批准号:
8403778 - 财政年份:2010
- 资助金额:
$ 34.28万 - 项目类别:
相似国自然基金
AGGF1-SIRT2轴通过调控自噬抑制肾癌发生的分子机制研究
- 批准号:81902860
- 批准年份:2019
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
负载类血管生成因子3的可注射水凝胶局部控释体系构建及其对糖尿病下肢缺血病变的治疗作用
- 批准号:51973125
- 批准年份:2019
- 资助金额:58 万元
- 项目类别:面上项目
LncRNA-NEAT1通过ceRNA作用促进卵巢癌血管新生的机制研究
- 批准号:81860515
- 批准年份:2018
- 资助金额:34.8 万元
- 项目类别:地区科学基金项目
血管生成因子AGGF1在机体抗DNA病毒天然免疫中的作用及调控机制
- 批准号:81801556
- 批准年份:2018
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
IL-21致KC分泌促血管生成因子调控银屑病微血管异常增生的机制研究
- 批准号:81703130
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Developing a novel disease-targeted anti-angiogenic therapy for CNV
开发针对 CNV 的新型疾病靶向抗血管生成疗法
- 批准号:
10726508 - 财政年份:2023
- 资助金额:
$ 34.28万 - 项目类别:
Placental Organoids for Modeling and Treating Preeclampsia
用于建模和治疗先兆子痫的胎盘类器官
- 批准号:
10464766 - 财政年份:2022
- 资助金额:
$ 34.28万 - 项目类别:
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma
核心蛋白聚糖和扩散 MRI 在复发性胶质母细胞瘤抗 VEGF 疗效中的作用
- 批准号:
10590620 - 财政年份:2022
- 资助金额:
$ 34.28万 - 项目类别:
Cardiomyocyte Non-autonomous Factors and Cardiac Regeneration in Large Mammals
大型哺乳动物心肌细胞非自主因素与心脏再生
- 批准号:
10680563 - 财政年份:2022
- 资助金额:
$ 34.28万 - 项目类别: